Editas Medicine Announces Nomination of EDIT-401 as Lead In Vivo Development Candidate for LDL-C Reduction, Aiming for Human Data by 2026

Reuters

09/02

<a href="https://laohu8.com/S/EDIT">Editas Medicine</a> Announces Nomination of EDIT-401 as Lead In Vivo Development Candidate for LDL-C Reduction, Aiming for Human Data by 2026

Editas Medicine Inc., a gene editing company, has announced the nomination of EDIT-401 as their lead in vivo development candidate. EDIT-401 is an experimental therapy aimed at significantly reducing LDL cholesterol (LDL-C) levels. In studies conducted on non-human primates, a single dose of EDIT-401 achieved an approximate 90% reduction in mean LDL-C levels. The company is planning to present human proof-of-concept data by the end of 2026. Editas Medicine maintains a strong cash position, with operational funding secured until the second quarter of 2027. A company-sponsored webinar on EDIT-401 is scheduled.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521261-en) on September 02, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564381809"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564381809\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564381809?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564381809","market":"fut","top_or_hot":-1,"title":"Editas Medicine Announces Nomination of EDIT-401 as Lead In Vivo Development Candidate for LDL-C Reduction, Aiming for Human Data by 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EDIT\">Editas Medicine</a> Announces Nomination of EDIT-401 as Lead In Vivo Development Candidate for LDL-C Reduction, Aiming for Human Data by 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Editas Medicine Inc., a gene editing company, has announced the nomination of EDIT-401 as their lead in vivo development candidate. EDIT-401 is an experimental therapy aimed at significantly reducing LDL cholesterol (LDL-C) levels. In studies conducted on non-human primates, a single dose of EDIT-401 achieved an approximate 90% reduction in mean LDL-C levels. The company is planning to present human proof-of-concept data by the end of 2026. Editas Medicine maintains a strong cash position, with operational funding secured until the second quarter of 2027. A company-sponsored webinar on EDIT-401 is scheduled.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521261-en) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Editas Medicine Announces Nomination of EDIT-401 as Lead In Vivo Development Candidate for LDL-C Reduction, Aiming for Human Data by 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEditas Medicine Announces Nomination of EDIT-401 as Lead In Vivo Development Candidate for LDL-C Reduction, Aiming for Human Data by 2026\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-02 19:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/EDIT\">Editas Medicine</a> Announces Nomination of EDIT-401 as Lead In Vivo Development Candidate for LDL-C Reduction, Aiming for Human Data by 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Editas Medicine Inc., a gene editing company, has announced the nomination of EDIT-401 as their lead in vivo development candidate. EDIT-401 is an experimental therapy aimed at significantly reducing LDL cholesterol (LDL-C) levels. In studies conducted on non-human primates, a single dose of EDIT-401 achieved an approximate 90% reduction in mean LDL-C levels. The company is planning to present human proof-of-concept data by the end of 2026. Editas Medicine maintains a strong cash position, with operational funding secured until the second quarter of 2027. A company-sponsored webinar on EDIT-401 is scheduled.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521261-en) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDLzrG2W:1","article_id":"2564381809","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564381809","pubTimestamp":1756810865,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Editas Medicine Announces Nomination of EDIT-401 as Lead In Vivo Development Candidate for LDL-C Reduction, Aiming for Human Data by 2026. Editas Medicine Inc., a gene editing company, has announced the nomination of EDIT-401 as their lead in vivo development candidate. EDIT-401 is an experimental therapy aimed at significantly reducing LDL cholesterol  levels. In studies conducted on non-human primates, a single dose of EDIT-401 achieved an approximate 90% reduction in mean LDL-C levels. The company is planning to present human proof-of-concept data by the end of 2026. Editas Medicine maintains a strong cash position, with operational funding secured until the second quarter of 2027. A company-sponsored webinar on EDIT-401 is scheduled.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inter","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","EDIT":"Editas Medicine, Inc.","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4556":"基因编辑"},"translate_title":"Editas Medicine宣布提名EDIT-401为降低LDL-C的主要体内开发候选药物，目标是到2026年获得人体数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EDIT":0.9,"NDAQ":0.9},"content_text":"Editas Medicine Announces Nomination of EDIT-401 as Lead In Vivo Development Candidate for LDL-C Reduction, Aiming for Human Data by 2026\n    \n\n        Editas Medicine Inc., a gene editing company, has announced the nomination of EDIT-401 as their lead in vivo development candidate. EDIT-401 is an experimental therapy aimed at significantly reducing LDL cholesterol (LDL-C) levels. In studies conducted on non-human primates, a single dose of EDIT-401 achieved an approximate 90% reduction in mean LDL-C levels. The company is planning to present human proof-of-concept data by the end of 2026. Editas Medicine maintains a strong cash position, with operational funding secured until the second quarter of 2027. A company-sponsored webinar on EDIT-401 is scheduled.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521261-en) on September 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}